Ventas Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Ventas ha aumentado sus beneficios a una tasa media anual de 24.9%, mientras que los beneficios de la industria de Health Care REITs han experimentado un crecimiento de 8.7% anual. Los ingresos han ido creciendo a una tasa media de 9.6% al año. La rentabilidad financiera de Ventas es de 2%, y sus márgenes netos son de 4.3%.
Información clave
24.87%
Tasa de crecimiento de los beneficios
20.42%
Tasa de crecimiento del BPA
| Crecimiento de la industria Health Care REITs | -12.20% |
| Tasa de crecimiento de los ingresos | 9.64% |
| Rentabilidad financiera | 2.01% |
| Margen neto | 4.26% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Ventas: Senior Housing Growth Appears Priced In
Apr 28
VTR: Higher Dividend And Earnings Outlook Will Support Bullish Cash Flow Trajectory
Analysts have adjusted their price target on Ventas slightly higher to $93.10 from $92.95, reflecting updated views on fair value, discount rate, profit margin, and future P/E assumptions. What's in the News Company issued full year 2026 earnings guidance, projecting net income attributable to common stockholders of US$260 million to US$310 million, or US$0.52 to US$0.62 per share (Company guidance) Board of Directors declared a quarterly cash dividend of US$0.52 per share, described as an 8% increase, payable on April 16, 2026 to stockholders of record on March 31, 2026 (Company announcement) Management linked the dividend decision to expectations for cash flow growth and a positive outlook, which indicates how they are currently thinking about capital returns to shareholders (Company announcement) Valuation Changes Fair Value: Price target moved slightly to $93.10 from $92.95, a small upward adjustment.VTR: Higher Dividend And Earnings Outlook Will Support Bullish Future P/E
Analysts have adjusted their fair value estimate for Ventas slightly higher to $92.95 from $92.50. This reflects updated views on the discount rate, revenue growth, profit margin, and expected future P/E levels.VTR: 2026 Dividend Increase And Earnings Guidance Will Support Bullish P/E Outlook
Analysts now place Ventas' fair value at $92.50, up from $90.90. This reflects updated assumptions around discount rates, revenue growth, profit margins and future P/E levels.VTR: 2026 Earnings Outlook And Dividend Increase Will Support Balanced P/E Expectations
Analysts have nudged their price target on Ventas up by about $1, reflecting slightly adjusted fair value, discount rate, and forward P/E assumptions in their models. What's in the News Ventas issued full year 2026 earnings guidance, projecting net income attributable to common stockholders in a range of $260m to $310m, or $0.52 to $0.62 per share (company guidance).VTR: 2026 Earnings Guidance And Dividend Policy Will Support P/E Upside
Analysts have increased their price target on Ventas from $87.75 to $89.50. The change reflects small adjustments to their model assumptions regarding the discount rate, revenue growth, profit margin and future P/E expectations.VTR: Steady Fair Value And 2026 Guidance Will Support P/E Upside
Analysts have lifted their price target on Ventas from $85.65 to $87.75, citing updated assumptions that combine slightly lower revenue growth with higher expected profit margins, a reduced discount rate, and a lower future P/E multiple. What's in the News Board of Directors declared a quarterly dividend of $0.52 per share, which the company describes as an 8% increase.VTR: Steady Fair Value And Higher 2025 Guidance Will Support P/E Upside
Analysts have kept their fair value estimate for Ventas steady at US$85.65, with only marginal tweaks to inputs such as the discount rate, profit margin and forward P/E assumptions that guide the updated price target rationale. What's in the News Ventas updated its full-year 2025 earnings guidance, with attributable net income per share now expected in a range of US$0.49 to US$0.52, compared with the prior range of US$0.47 to US$0.52 (Key Developments).VTR: Raised 2025 Earnings Guidance Will Support Attractive Forward P/E Upside
Analysts now set their fair value estimate for Ventas at $85.65, up slightly from $85.15. This reflects small adjustments to assumptions for the discount rate, revenue growth, profit margin, and forward P/E ratio.VTR: Full Year 2025 Guidance Will Support Steady Earnings Outlook
Analysts have modestly raised their price target on Ventas to approximately 85.15 dollars from 84.70 dollars, reflecting slightly lower discount rate assumptions and a marginally higher long term valuation multiple. What's in the News Raised full year 2025 earnings guidance, increasing expected attributable net income per share to a range of 0.49 to 0.52 dollars from the prior 0.47 to 0.52 dollars (company guidance) Valuation Changes Fair Value: risen slightly from 84.70 dollars to 85.15 dollars per share, reflecting a modest upward adjustment in intrinsic valuation.VTR: Full Year 2025 Guidance Will Support Improved Profitability Outlook
Analysts have modestly raised their price target on Ventas from 82.95 dollars to 84.70 dollars, citing slightly faster anticipated revenue growth, marginally improved profit margins, and a lower discount rate that together support a higher future earnings multiple. What's in the News Ventas raised its full year 2025 earnings guidance, now expecting attributable net income per share of 0.49 to 0.52 dollars, up from the prior range of 0.47 to 0.52 dollars (company guidance) Valuation Changes Fair Value Estimate has risen slightly to 84.70 dollars from 82.95 dollars, reflecting a modestly higher intrinsic valuation.VTR: Full Year 2025 Guidance Will Drive Improved Profitability Outlook
Analysts have raised their price target for Ventas from $79.90 to $82.95, citing stronger revenue growth and improved profit margin projections as key factors supporting the upward revision. What's in the News Ventas, Inc.VTR: Full Year 2025 Guidance Update Will Support Balanced Valuation Outlook
Analysts have revised their price target for Ventas upward from $78.25 to $79.90. They cite slight improvements in fair value estimates and lower discount rates as reasons for the adjustment.VTR: Future Expansion And Stable Income Will Balance Sector Opportunities And Risks
Analysts have raised their price target for Ventas from $77.39 to $78.25. This reflects increased optimism about the company’s revenue growth prospects and modest adjustments in profitability expectations.Increasing Aging Demand Will Reshape Senior Housing And Medical Offices
Ventas’s consensus analyst price target saw a marginal increase to $77.28, with minimal changes in both future P/E and net profit margin, indicating little shift in the company’s underlying valuation metrics. What's in the News Ventas raised its 2025 earnings guidance, now expecting attributable net income per share of $0.47–$0.52, compared to the prior range of $0.43–$0.53.Why Ventas Is Poised For Strong Long-Term Returns
Apr 08Ventas: Growth Set To Continue In The Years Ahead
Nov 10Ventas: Net Operating Income Growth Concentrated In Senior Housing
Aug 25Ventas: 4 Reasons To Be Cautious As Bulls Try And Sell Demographic Boom 2.0
Jun 10Ventas: The Silver Tsunami Vs. A Decade Of Underperformance
Mar 27Desglose de ingresos y gastos
Cómo gana y gasta dinero Ventas. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 6,113 | 260 | 187 | 0 |
| 31 Dec 25 | 5,817 | 251 | 177 | 0 |
| 30 Sep 25 | 5,544 | 238 | 178 | 0 |
| 30 Jun 25 | 5,275 | 191 | 173 | 0 |
| 31 Mar 25 | 5,056 | 142 | 167 | 0 |
| 31 Dec 24 | 4,889 | 81 | 163 | 0 |
| 30 Sep 24 | 4,764 | -67 | 158 | 0 |
| 30 Jun 24 | 4,673 | -157 | 156 | 0 |
| 31 Mar 24 | 4,581 | -73 | 153 | 0 |
| 31 Dec 23 | 4,500 | -41 | 149 | 0 |
| 30 Sep 23 | 4,359 | 5 | 146 | 0 |
| 30 Jun 23 | 4,256 | 77 | 148 | 0 |
| 31 Mar 23 | 4,173 | -69 | 147 | 0 |
| 31 Dec 22 | 4,154 | -47 | 145 | 0 |
| 30 Sep 22 | 4,079 | -43 | 140 | 0 |
| 30 Jun 22 | 4,019 | 16 | 135 | 0 |
| 31 Mar 22 | 3,921 | 145 | 132 | 0 |
| 31 Dec 21 | 3,818 | 49 | 130 | 0 |
| 30 Sep 21 | 3,760 | 200 | 131 | 0 |
| 30 Jun 21 | 3,701 | 152 | 133 | 0 |
| 31 Mar 21 | 3,703 | -91 | 130 | 0 |
| 31 Dec 20 | 3,790 | 439 | 130 | 0 |
| 30 Sep 20 | 3,847 | 340 | 135 | 0 |
| 30 Jun 20 | 3,911 | 413 | 143 | 0 |
| 31 Mar 20 | 3,925 | 780 | 158 | 0 |
| 31 Dec 19 | 3,859 | 433 | 159 | 0 |
| 30 Sep 19 | 3,781 | 484 | 163 | 0 |
| 30 Jun 19 | 3,720 | 501 | 162 | 0 |
| 31 Mar 19 | 3,714 | 457 | 156 | 0 |
| 31 Dec 18 | 3,702 | 409 | 146 | 0 |
| 30 Sep 18 | 3,668 | 740 | 148 | 0 |
| 30 Jun 18 | 3,646 | 1,252 | 142 | 0 |
| 31 Mar 18 | 3,607 | 1,237 | 139 | 0 |
| 31 Dec 17 | 3,568 | 1,357 | 135 | 0 |
| 30 Sep 17 | 3,560 | 1,172 | 132 | 0 |
| 30 Jun 17 | 3,527 | 707 | 130 | 0 |
| 31 Mar 17 | 3,481 | 699 | 129 | 0 |
| 31 Dec 16 | 3,447 | 650 | 127 | 0 |
| 30 Sep 16 | 3,410 | 569 | 123 | 0 |
| 30 Jun 16 | 3,369 | 465 | 124 | 0 |
| 31 Mar 16 | 3,331 | 453 | 125 | 0 |
| 31 Dec 15 | 3,284 | 407 | 128 | 0 |
| 30 Sep 15 | 3,171 | 366 | 129 | 0 |
| 30 Jun 15 | 3,049 | 412 | 126 | 0 |
Ingresos de calidad: VTR tiene una única gran pérdida de $66.2M que afecta a sus resultados financieros de los últimos 12 meses de 31st March, 2026.
Margen de beneficios creciente: Los actuales márgenes de beneficio (4.3%) de VTR son superiores a los del año pasado (2.8%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: VTR ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 24.9% al año.
Acelerando crecimiento: El crecimiento de los beneficios de VTR en el último año (83%) supera su media de 5 años (24.9% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de VTR en el último año (83%) superó al de la industria Health Care REITs 20.4%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de VTR (2%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/04 04:12 |
| Precio de las acciones al final del día | 2026/05/01 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Ventas, Inc. está cubierta por 40 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jacob Kilstein | Argus Research Company |
| David Rodgers | Baird |
| Amanda Sweitzer | Baird |